- Home
- PANW vs GILD Comparison
PANW vs GILD Comparison
Compare PANW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | GILD |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.3B | 168.6B |
| IPO Year | 2012 | 2002 |
Fundamental Metrics
Financial Performance| Metric | PANW | GILD |
|---|---|---|
| Price | $242.29 | $129.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 39 | 18 |
| Target Price | ★ $216.28 | $148.39 |
| AVG Volume (30 Days) | ★ 6.2M | 5.0M |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.55% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | 1.07 | ★ 1.61 |
| Revenue | $2,273,100,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $24.93 | $4.68 |
| Revenue Next Year | $19.97 | $6.04 |
| P/E Ratio | $221.96 | ★ $81.97 |
| Revenue Growth | ★ 29.04 | 9.98 |
| 52 Week Low | $139.57 | $103.03 |
| 52 Week High | $239.15 | $157.29 |
Technical Indicators
Market Signals| Indicator | PANW | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 86.14 | 39.39 |
| Support Level | $179.81 | $128.32 |
| Resistance Level | N/A | $142.33 |
| Average True Range (ATR) | 8.84 | 3.29 |
| MACD | 5.68 | 0.16 |
| Stochastic Oscillator | 95.56 | 16.04 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).